E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
NA |
patients atteints d’un Carcinome Hépato-Cellulaire (CHC) (BCLC A) ayant un mauvais pronostic, et traités par ablation percutanée en intention curatrice |
|
E.1.1.1 | Medical condition in easily understood language |
NA |
Carcinome Hépato-Cellulaire |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess local recurrence-free survival during a 1 year follow-up after PA procedure.
Local recurrence is defined as emergence of irregular areas enhanced at arterial phase followed by washout at portal phase observed next to the ablation zone.
Justification of 1-yr follow-up period: HCC recurrence is usually divided in the literature as time-related recurrence: “early” within the two years following the ablation and “late” after two years (reference: Imamura H, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. Journal of hepatology 2003;38:200-207).
Early relapse is usually related to tumour features whereas late relapse is related to de novo carcinogenesis.
|
NA |
|
E.2.2 | Secondary objectives of the trial |
- To assess the changes of tumorous and non-tumorous perfusion parameters observed with MRI after of neoadjuvant treatment, and before the PA procedure
- To assess the Per nodule rates of early response (one month) after a single procedure of PA
- To assess the incidences of intra segmental/ extra segmental distant recurrence
- To assess the overall survival at 1 and 2 years following PA procedure
- To assess the compliance to neoadjuvant and adjuvant treatments
- To assess the tolerance of lenvatinib in the setting of neo- and adjuvant therapy to PA
|
NA |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Male or female patients ≥ 18 years
- Histological diagnosis of HCC, whether new or recurrent following a prior curative therapeutic management > 6 months.
- Barcelona Clinical Liver Cancer(BCLC) stage Category A
- Comprising at least one of the following the following characteristics:
- Serum AFP>100 ng/mL
- Infiltrative form
- Macro-trabecular subtype
- Patients with HCC amenable for PA as assessed by multidisciplinary board corresponding to the following extension:
o Uninodular HCC≥ 2 cm and ≤ 5 cm, no macroscopic vascular invasion
o Multinodular maximum 3 nodules ≤ 3 cm, no macroscopic vascular invasion
- At least one uni-dimensional measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to modified RECIST for HCC
- Absence of any portal vein thrombosis
- Liver function status Child-Pugh Class A
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1
- Adequate bone marrow, liver and renal function as assessed by the following laboratory tests:
o Hemoglobin > 8.5 g/dL
o Absolute neutrophil count ≥ 1500/mm3
(≥ 1200/mm3 for black/African, American)
o Platelet count ≥ 60,000/ mm3
o Total bilirubin ≤ 2 mg/dL
o Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x upper limit of normal (ULN)
o Serum creatinine ≤ 1.5 x ULN
o Prothrombine time-international normalized ratio (PT-INR) < 2.3 and PTT < 1.5
o Glomerular Filtration Rate (GFR) ≥ 30 mL/min/1.73 m2
- Life expectancy ≥ 3 months
- Women of childbearing potential (WOCBP) need to accept one effective method of contraception until 1 month after the last lenvatinib intake and avoid pregnancy
- Patients who are sexually active with WOCBP partners need to accept one effective method of contraception until 1 month after lenvatinib intake and men must agree to use adequate contraception
- Patients affiliated to a Social Security System
- Written informed consent signed
- Patient under guardianship or curatorship*
- Satisfactory nutritional status (BMI>18 kg/m² for patients under 70 years old, or ≥21 kg/m² for the patients over 70 years old)der
|
NA |
|
E.4 | Principal exclusion criteria |
- Patients with recurrence of HCC occurring less than six months after a curative treatment regarded as successful
- BCLC stage >A (1 single lesion >5cm or more than 3 lesions ore multifocal HCC >3cm or vascular invasion or extra-hepatic spread)
- Patients with contraindications to PA
*Pacemakers or patients who have a history of cardiac arrhythmias or irregular heartbeats (in case of electroporation procedure)
*Ascites
*Coagulopathy
*Ongoing bacterial infection
- Patients with contraindication to contrast medium intravenous injection either gadolinium or iodinate
- Prior liver transplantation or candidates for liver transplantation
- Prior systemic treatment for HCC (chemotherapy, any other TKI, immunotherapy)
- Patients with large oesophageal varices at risk of bleeding that are not being treated with conventional medical intervention
- Past or concurrent history of neoplasm other than HCC, except for in situ carcinoma of the cervix uteri and/or non-melanoma skin cancer and superficial bladder tumours. Any cancer curatively treated > 3 years prior to study entry is permitted
- Major surgical procedure or significant traumatic injury within 28 days before enrolment
- Congestive heart failure New York Heart Association (NYHA) ≥ class 2
- Unstable angina or myocardial infarction within the past 6 months before enrolment
-Uncontrolled blood pressure to systolic BP >140mmHg or diastolic BP >90 mmHg in spite of an optimized regimen of antihypertensive medication
- Patients with phaeochromocytoma
- Refractory ascites according to EASL guidelines definition (ascites that cannot be mobilized or the early recurrence of which cannot be prevented because of a lack of response to sodium restriction and diuretic treatment)
- Persistent proteinuria of NCI-CTCAE version 4.0 ≥ Grade 3
- Ongoing infection > Grade 2 according to NCI-CTCAE version 4.0. Hepatitis B is allowed if no active replication is present (below 100 IU/mL). Hepatitis C is allowed if no antiviral treatment is required
- Clinically significant bleeding NCI-CTCAE version 4.0 ≥ Grade 3 within 30 days before enrolment
- Any psychological, familial, sociological, geographical or illness or medical condition that could jeopardize the safety of the patient and/or his compliance with the study protocol and follow-up procedure
- Non-healing wound, ulcer or bone fracture
- Known hypersensitivity to the study drug or excipients in the formulation
- Any malabsorption condition
- Breast feeding
- Pregnancy
- Patient unable to swallow oral medication |
NA |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Local recurrence-free survival during a 1-year follow-up after lenvatinib neoadjuvant/adjuvant therapy and PA procedure (see definition above).
Recurrence rates (whether local or distant) will be assessed using imaging techniques as recommended by international guidelines (every 3-months US and CT/MRI during one year). Patients who will meet primary endpoint will be alive 1 year after PA procedure without evidence of local recurrence on 3-months MRI evaluations.
|
NA |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1 year after PA procedure without evidence of local recurrence on 3-months MRI evaluations. |
NA |
|
E.5.2 | Secondary end point(s) |
- Changes of tumorous and non-tumorous perfusion parameters observed with MRI after one month of neoadjuvant treatments
- Per nodule rates of early response (one month) after a single procedure of PA
- Incidences of intra segmental/ extra segmental distant recurrence
- Assessment of overall survival at 1 and 2 years following PA procedure: patients will meet this endpoint if they are alive with or without HCC recurrence 1 year, and 2 years after PA procedure. Causes and date of death will be specified when applicable during this timeframe.
- Assessment of tolerance of lenvatinib: adverse events related will be monitored according to manufacturer guidelines and recommendation.
- Compliance to neoadjuvant and adjuvant treatments
- Frequency of SAEs and discontinuations due to AEs
|
NA |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1 and 2 years following PA procedure |
NA |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 11 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |